Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q3 2022 Earnings Presentation
28 slides from Marinomed Biotech's earnings presentation, Nov 21, 2022
Slide 1: Investor Presentation Q3 2022
Investor Presentation Q3 2022 Andreas Grassauer, CEO, Eva Prieschl-Grassauer, CSO, Pascal Schmidt, CFO 21st November 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Strategy Update • Financials Q3 2022 Pascal Schmidt, CFO • Spotlight on SOLV4U Eva Prieschl-Grassauer, CSO • Investment highlights & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Marinomed investment highlights
Marinomed investment highlights Solid existing business, broad late-stage pipeline • Highly experienced management team • Solid growth perspective with existing product portfolio • Lean and efficient business model – with cost efficient approach along entire value chain • Focus on of early clinical
Slide 5: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2022+ 2023/24 2025+ • Maximize product sales • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen
Slide 6: Highlights in 2022 to date
Highlights in 2022 to date Delivering on our promises Feb. – €6m EIB financing tranche after meeting all predefined milestones Apr. – New agreement with Hanmi for marketing of Carragelose in South Korea Apr. – Strong 2021 financials and record sales in Q1/22 May – Procter & Gamble (P&G) for Carragel
Slide 7: Marinomed has built a proven track record
Marinomed has built a proven track record Successes in the therapeutic areas Virology Immunology • Carragelose effective against respiratory viruses • First aqueous steroid solution, all other major competitors are suspensions • Series of clinical studies supports efficacy • Generating sustainable r
Slide 8: The US market Cough, Cold & Allergy (CCA)
The US market Cough, Cold & Allergy (CCA) With $7.9bn the North American Cough, Cold & Allergy market is almost double the size of Western Europe ($4.3bn) CHC market by category 2021 Leading CCA brands 2021 (global sales) North America Western Europe Brand Owner $mn 21/20 1 Vicks P&G 1418 +12% 2 Hal
Slide 9: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Strategy Update • Financials Q3 2022 Pascal Schmidt, CFO • Spotlight on SOLV4U Eva Prieschl-Grassauer, CSO • Investment highlights & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed Biotech AG 9
Slide 10: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and encouraging SOLV4U development Y-o-Y comparison of quarterly revenues (m€) Comments 7.1 Key growth drivers 5.7 • Revenues rose from €5.7m to €7.1m (+24%); therein sale of goods €6.5m (up from €5.4m) 2.2 2.4 2.5 2.5 2.2 1.0 • SOLV4U gener
Slide 11: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – improved EBIT €m 9M 2022 9M 2021 1 9M 2022 9M 2021 1 Sale of goods 6.5 5.4 Revenues 7.1 5.7 Cost of goods sold -4.5 -3.6 2 Other income 0.6 1.4 Margin 31.6% 33.6% Materials expenses -4.6 -3.9 3 •2 Primarily consisting of research premium and grant
Slide 12: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q3 2022 FY 2021 1 Inventories €m Q3 2022 FY 2021 Assets Goods for sale 0.3 0.1 Intangible assets 1.9 2.0 Unfinished goods 0.4 0.1 Property, plant and equipment 6.3 6.4 Raw materials 1.3 0.8 Deposits and other non-current Total inventories 2.0 1.0 0.0
Slide 13: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q3 2022 FY 2021 •1 Capital increases through convertible note funding program Equity and liabilities Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m) and ERP/aws and NÖBEG real estate refinancing (€4.8m) Capital reserves
Slide 14: Comfortable cash reach
Comfortable cash reach Low cash drain due to profitable revenues and inflows from convertible bond program • Ended December 2021 with €5.8m in cash • Raised +€7.3m in net cash through EIB (€6.0m), NÖBEG (€0.2m) and CNFP1 (€1.2m) • Received +€0.7m in milestones • Earned +€2.5m net cash through profit
Slide 15: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Strategy Update • Financials Q3 2022 Pascal Schmidt, CFO • Spotlight on SOLV4U Eva Prieschl-Grassauer, CSO • Investment highlights & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed Biotech AG 15
Slide 16: SOLV4U technology partnerships
SOLV4U technology partnerships Marinosolv technology is utilized for customers • Suitable for APIs1 in all stages of development • 5 projects in 2022 – significantly increased solubility was achieved • 2 follow-on projects © Marinomed Biotech AG 1active pharmaceutical ingredients 16
Slide 17: Marinosolv® technology
Marinosolv® technology Solubilization of API Benefits • Significantly increases bioavailability • Allows reduction of dose • Reduces pharmaceutical compounds in waste water • May reduce systemic side effects • Clinically proven Marinosolv allows the solubilization of highly • Patent protected hydrop
Slide 18: Marinosolv® enabled compounds
Marinosolv® enabled compounds Versatile technology allows solubilization of variety of small molecules *0.2% w/v solution of pazopanib hydrochloride in water has a pH of 2.2. At pH 5.5 pazopanib in Marinosolv is 52,000-fold more soluble than just in buffer. © Marinomed Biotech AG RdRP: RNA-dependent
Slide 19: Activities to support Business development
Activities to support Business development LinkedIn campaign (21 days) • >300.000 target group • 188 new followers (+213%) • 94 likes • 15x shared • 142.447 impressions • 28.594 views of video • 1292 clicks © Marinomed Biotech AG 19
Slide 20: SOLV4U – CPHI 2022
SOLV4U – CPHI 2022 > 150 meetings 10 new leads © Marinomed Biotech AG 20
Slide 21: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Strategy Update • Financials Q3 2022 Pascal Schmidt, CFO • Spotlight on SOLV4U Eva Prieschl-Grassauer, CSO • Investment highlights & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed Biotech AG 21
Slide 22: This keeps us busy
This keeps us busy Various projects require significant attention, but are rewarding • Despite lock-downs in Shanghai good Co-development and definition Execution with Luoxin for the Chinese territory progress in collaboration of regulatory path • Strong commitment visible …with the following partne
Slide 23: Outlook and timeline 2022/2023
Outlook and timeline 2022/2023 News flow / milestones • February – Draw down of €6m EIB financing tranche • April – New agreement with Hanmi for marketing of Carragelose in South Korea • April – Publication of strong 2021 financials News flow to • May – Procter & Gamble (P&G) for Carragelose product
Slide 24: Marinomed investment highlights
Marinomed investment highlights Solid existing business, broad late-stage pipeline • Highly experienced management team • Solid growth perspective with existing product portfolio • Lean and efficient business model – with cost efficient approach along entire value chain • Focus on of early clinical
Slide 25: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Strategy Update • Financials Q3 2022 Pascal Schmidt, CFO • Spotlight on SOLV4U Eva Prieschl-Grassauer, CSO • Investment highlights & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed Biotech AG 25
Slide 26: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar Stephanie Kniep November 21, 2022 Publication of the Results Q1-Q3 2022 Investor Relations April 19, 2023 Publication of the Annual Report 2022 phone: +43 2262 90300 226 e-mail: IR@marinomed.com May 23, 2023 Publication of the Results Q1 2023 Record
Slide 27: Thank you!
Thank you! © Marinomed Biotech AG 27
Slide 28: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Reduction of active ingredient • Use of renewable energy • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people living with diseases with limited or no treatment options • No. 1 in the gend